Blog Articles

Whether developing a force-sensing surgical instrument, a wearable monitoring device, or a handheld surgical tool, electronics engineers are frequently asked to fit increasingly sophisticated functionality into spaces that seem impossibly small. This is an even greater challenge when those devices must operate safely and reliably in clinical or surgical environments where performance, robustness, and regulatory compliance are non-negotiable.

Drug store diagnostics, like pregnancy tests and rapid COVID-19 tests are relied on every day by consumers around the world. These devices provide fairly accurate results, but many users might find the faint lines on lateral flow assays hard to read.

Respiratory drug delivery has evolved far beyond the familiar “inhale and press” inhaler. Today, electronics are robust, mature, and cheap enough to optimize how inhalation devices generate aerosols, deliver medication accurately, monitor patient technique, and support adherence. From vibrating mesh nebulisers to breath-actuated smart inhalers, the integration of electronics is redefining what inhaled therapies can achieve.

The global healthcare industry is entering a period of profound transformation. Geopolitical realignments, economic pressure, and regulatory change are reshaping how pharmaceutical and medical device companies design, develop, and manufacture and distribute products. For MedTech innovators and their partners, anticipating these shifts is no longer optional, it is a prerequisite for sustainable growth.

Taking a low cost/high volume trauma device from a 3D printed prototype to an injection moulded product

We enter 2026 as a new reality is forming. It will not be “business as usual”. Geopolitical forces in the largest market for pharmaceuticals, the United States, are likely to mean substantial changes. In this article we cover those changes, the incretin juggernaut and finally the march of technical progress with “minitablet” dispensers, large volume injectors, and dual chamber devices.

Cell and gene therapies (CGTs) are a rapidly developing area of technology, and therapies using chimeric antigen receptor (CAR) T-cells, stem cell and other gene-edited cell products are transforming the pharmaceutical landscape. These new therapies essentially exploit cells as living drugs, capable of proliferating and generating a sustained, targeted immune response to treat disease sites in the patient’s body.

Requirements for moisture control in dry powder inhaler development and definition of desiccant packaging solutions.

Emergency use devices have been a long-standing part of the drug-device combination product market, with early autoinjectors being developed for military crisis applications and then adapted for general use to deliver epinephrine. From that point, the field has diversified, with the EpiPen leading the way for a range of intramuscular crisis autoinjectors, followed by the emergence of naloxone nasal sprays and autoinjectors for the treatment of opioid overdose, as well as subcutaneous…

The demand for reliable, user-friendly autoinjectors continues to grow. These devices must ensure safe, consistent performance for users, including those with limited dexterity. A leading pharmaceutical client approached Springboard to help develop a critical mechanism within their next-generation autoinjector that safely and reliably removes the syringe’s rigid needle shield (RNS) just before use.